[go: up one dir, main page]

CL2022001431A1 - Combination of mirtazapine and tizanidine for use in pain disorders - Google Patents

Combination of mirtazapine and tizanidine for use in pain disorders

Info

Publication number
CL2022001431A1
CL2022001431A1 CL2022001431A CL2022001431A CL2022001431A1 CL 2022001431 A1 CL2022001431 A1 CL 2022001431A1 CL 2022001431 A CL2022001431 A CL 2022001431A CL 2022001431 A CL2022001431 A CL 2022001431A CL 2022001431 A1 CL2022001431 A1 CL 2022001431A1
Authority
CL
Chile
Prior art keywords
tizanidine
mirtazapine
combination
pain disorders
ranges
Prior art date
Application number
CL2022001431A
Other languages
Spanish (es)
Inventor
Gerovich BENIASHVILI Allan
Alekseevna MOROZOVA Margarita
Eduardovich Zapolsky Maksim
Original Assignee
Valenta Intellekt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valenta Intellekt Ltd filed Critical Valenta Intellekt Ltd
Publication of CL2022001431A1 publication Critical patent/CL2022001431A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a la industria química y farmacéutica y la medicina y se refiere a una nueva composición farmacéutica que comprende mirtazapina y tizanidina o sales farmacéuticamente aceptables de las mismas, para el tratamiento de trastornos del dolor, caracterizándose dicha composición por que el contenido de mirtazapina varía de 15 a 60 mg y el contenido de tizanidina varía de 6 a 24 mg, en donde la proporción en masa de mirtazapina a tizanidina como bases libres es de 2,5:1. La invención también se refiere a una combinación farmacéutica, un fármaco terapéutico, al uso del mismo y a un método para tratar un trastorno del dolor.The invention refers to the chemical and pharmaceutical industry and medicine and refers to a new pharmaceutical composition comprising mirtazapine and tizanidine or pharmaceutically acceptable salts thereof, for the treatment of pain disorders, said composition being characterized in that the content of mirtazapine ranges from 15 to 60 mg and tizanidine content ranges from 6 to 24 mg, where the mass ratio of mirtazapine to tizanidine as free bases is 2.5:1. The invention also relates to a pharmaceutical combination, a therapeutic drug, the use thereof, and a method of treating a pain disorder.

CL2022001431A 2019-12-02 2022-05-31 Combination of mirtazapine and tizanidine for use in pain disorders CL2022001431A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2019139129A RU2736713C1 (en) 2019-12-02 2019-12-02 Combination of mirtazapine and tizanidine for use in pain disorders

Publications (1)

Publication Number Publication Date
CL2022001431A1 true CL2022001431A1 (en) 2023-03-17

Family

ID=73460960

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022001431A CL2022001431A1 (en) 2019-12-02 2022-05-31 Combination of mirtazapine and tizanidine for use in pain disorders

Country Status (10)

Country Link
KR (1) KR20220110259A (en)
CN (1) CN114761017B (en)
BR (1) BR112022010718A2 (en)
CL (1) CL2022001431A1 (en)
IL (1) IL293562A (en)
MX (1) MX2022006581A (en)
RU (1) RU2736713C1 (en)
SA (1) SA522432821B1 (en)
TN (1) TN2022000140A1 (en)
WO (1) WO2021112724A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2657481A1 (en) * 2006-07-21 2008-01-24 Queen's University At Kingston Methods and therapies for potentiating a therapeutic action of an alpha- 2 adrenergic receptor agonist and inhibiting and/or reversing tolerance to alpha- 2 adrenergic receptor agonists
CN101318020B (en) * 2007-06-06 2011-09-28 四川科瑞德制药有限公司 Anti-anxiety or/and dumps medicament composition and uses thereof
AU2009207796B2 (en) * 2008-01-25 2014-03-27 Grunenthal Gmbh Pharmaceutical dosage form
US20100159001A1 (en) * 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
WO2013061161A2 (en) * 2011-10-28 2013-05-02 Green Bcn Consulting Services Sl New combination therapies for treating neurological disorders
RU2509560C1 (en) * 2013-03-22 2014-03-20 Общество С Ограниченной Ответственностью "Валента-Интеллект" New therapeutic combinations of mirtazapine applicable in pain conditions

Also Published As

Publication number Publication date
RU2736713C1 (en) 2020-11-19
BR112022010718A2 (en) 2023-03-14
SA522432821B1 (en) 2023-11-29
KR20220110259A (en) 2022-08-05
CN114761017A (en) 2022-07-15
CN114761017B (en) 2024-02-02
WO2021112724A1 (en) 2021-06-10
TN2022000140A1 (en) 2024-01-02
IL293562A (en) 2022-08-01
MX2022006581A (en) 2022-08-10

Similar Documents

Publication Publication Date Title
CO2021008988A2 (en) Combination of dextromethorphan and bupropion for the treatment of depression
MX2024010140A (en) NEW METHODS.
MX2020009246A (en) USE OF THE PCSK9 INHIBITOR TO REDUCE CARDIOVASCULAR RISK.
MX2019003173A (en) Combination therapy with controlled-release cnp agonists.
MX393855B (en) COMBINATION THERAPY INCLUDING A RAF INHIBITOR AND TRAMETINIB
CO2023013050A2 (en) Psilocybin compositions, methods of preparing them and methods of using them
MX2023003677A (en) Hsd17b13 inhibitors and uses thereof.
MX2023003678A (en) Hsd17b13 inhibitors and uses thereof.
Kukushkin et al. Results of a randomized double blind parallel study on the efficacy and safety of tolpersione in patients with acute nonspecific low back pain
BR112012030641B8 (en) Uses and compositions for oral pharmaceutical therapy
Alcocer‐Gómez et al. Effect of coenzyme Q10 on psychopathological symptoms in fibromyalgia patients
DOP2023000171A (en) PHARMACEUTICAL DOSAGE FORMS COMPRISING (4S)24CHLORINE4ETHYL73FLUORO35METHOXY32.5DIOXO14(TRIFLUOROMETHYL)32H6AZA3(4.1) PYRIDINE1(1)[1,2,3]TRIAZOLA2(1,2),7(1)DIBENZENEHEPTAPHAN74CARBOXAMIDE
ZA202000028B (en) Use of vibegron to treat overactive bladder
MX2023003675A (en) Hsd17b13 inhibitors and uses thereof.
CL2022001431A1 (en) Combination of mirtazapine and tizanidine for use in pain disorders
CO2025007025A2 (en) Oral compactable formulations of ibutamoren
AR101227A1 (en) COMBINATIONS OF A N-TIAZOLIL-4-PHENOXIBENCENOSULFONAMIDE DERIVATIVE AND A PHARMACEUTICALLY ACTIVE AGENT SELECTED FROM GABAPENTINE AND PREGABALINE TO TREAT PAIN
ECSP22092205A (en) LEVILIMAB AQUEOUS PHARMACEUTICAL COMPOSITION AND ITS USE
Dalkiran et al. Phantom limb pain treated with duloxetine: a case series
BR112018009476A2 (en) plasminogen dosage regimen for wound healing
UY38340A (en) SYNERGIC PHARMACEUTICAL COMBINATION INCLUDING TRAMADOL HYDROCHLORIDE AND PREGABALIN, AND THEIR USE FOR THE TREATMENT OF NEUROPATHIC PAIN
AR120453A1 (en) COMBINATION OF A BTK INHIBITOR AND AN MDM2 INHIBITOR FOR THE TREATMENT OF CANCER
EA202000300A1 (en) PHARMACEUTICAL KIT FOR COMBINED THERAPY FOR COVID-19 (SARS-CoV-2) AND METHOD FOR ITS USE
DOP2024000193A (en) CELECOXIB-ACETAMINOPHEN COMBINATION WITH ENHANCED STABILITY AND PROCEDURE FOR ITS PREPARATION
AR122344A1 (en) USE OF REBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS